Clinical Pharmacy

CP-108

EVALUATION OF CLINICAL PHARMACIST INTERVENTIONS IN A UNIVERSITY HOSPITAL LOCATED IN A RURAL AREA IN LEBANON

CP-107

USE OF BOTULINUM TOXIN TYPE A IN ESOPHAGEAL ACHALASIA: A CASE REPORT

CP-105

COST EFFECTIVENESS OF TICAGRELOR FOR CARDIOVASCULAR PREVENTION IN PATIENTS WITH ACUTE CORONARY SYNDROMES AND LOW-DOSE ASPIRIN IN SPAIN

CP-102

CARBOPLATIN – PACLITAXEL – BEVACIZUMAB BASED TREATMENT FOR NON-SMALL CELL LUNG ADVANCED CANCER PATIENTS: USE REVIEW

CP-100

STRATEGY FOR THE SIMPLIFICATION OF ANTIRETROVIRAL THERAPY: PROTEASE INHIBITOR MONOTHERAPY

CP-081

ROLE OF THE HOSPITAL PHARMACIST IN AUTOMATICALLY REMOVING PRESCRIPTION OF CONTINUOUS ANALGESIA PUMPS IN A TRAUMA SERVICE

CP-080

ANALYSIS OF ONDANSETRON PRESCRIPTION PRACTICES IN THE CARE OF POSTOPERATIVE NAUSEA AND VOMITING

CP-077

EVALUATION OF GLUTAMINE SUPPLEMENTATION IN PARENTERAL NUTRITION IN A GENERAL HOSPITAL

CP-074

COMPARISON THE DIFFERENT INCLUSION AND EXCLUSION CRITERIA FOR TREATMENT WITH ECULIZUMAB IN SPAIN

CP-069

ECONOMIC IMPACT OF BIOLOGICAL TREATMENTS IN RHEUMATIC DISEASES

CP-068

ANTIRETROVIRAL TREATMENT ADHERENCE IN PAEDIATRIC PATIENTS

CP-064

COMPARATIVE EFFICACY OF BIOLOGICAL DRUGS IN THE MAINTENANCE PHASE IN ADULT PATIENTS WITH MODERATE-SEVERE PLAQUE PSORIASIS

CP-062

SUBCUTANEOUSLY IMPLANTED PORT-CHAMBER CENTRAL VENOUS CATHETERS: PREVENTION AND CARE OF OCCLUSION

CP-060

AN INVESTIGATION INTO THE IMPACT OF A CLINICAL WARD PHARMACIST ON MEDICINES RETURNED TO PHARMACY FOR RE-USE OR DESTRUCTION

CP-059

CONGRUENCE OF SEVERITY RATINGS ASSIGNED BY TWO DRUG INTERACTION DATABASES IN HAEMOTOLOGICAL TREATMENT SHEETS

Pages